Chugai’s Q1 Sales Slide 5.9% on Drug Price Cuts, Gx, Frontloaded Actemra Exports

April 23, 2021
Chugai Pharmaceutical saw its revenue dwindle nearly 6% in the first quarter of 2021 over a year ago as drug price revisions in April last year and generic and biosimilar penetration for major products took a toll on its earnings...read more